Skip to main content

CD22 Positive clinical trials at UC Davis
1 research study open to eligible people

  • A Study of Experimental Inotuzumab Ozogamicin for Younger Patients With CD22 Positive B Acute Lymphoblastic Leukemia

    open to eligible people ages 1-21

    This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without harming normal cells.

    Sacramento, California and other locations

Last updated: